Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JADE101 · 1 trial · 1 indication
The proportion of participants who experience one or more adverse events that begin or worsen after the first dose of study drug
| Arm | Type | Description |
|---|---|---|
| JADE101 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| Name | Type | Description |
|---|---|---|
| JADE101 | DRUG | JADE101 is supplied as sterile solution to be administered by SC injection |
Inclusion Criteria: 1. Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent 2. eGFR ≥ 30 mL/min/1.73 m2 3. Biopsy-confirmed primary IgAN 4. Receiving stable and maximally tolerated doses of either ACEi or ARB as per...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 12 | PHASE3 | Zigakibart, Atrasentan, Iptacopan |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Vertex Pharmaceuticals Incorporated | VRTX | 4 | PHASE3 | Povetacicept, Sibeprenlimab |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Biogen Inc. | BIIB | 2 | PHASE3 | Felzartamab |
| Biohaven Ltd. | BHVN | 2 | PHASE3 | BHV-1400 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Sefaxersen |
| Travere Therapeutics, Inc. | TVTX | 1 | PHASE2 | Sparsentan |
| argenx SE Sponsored ADR | ARGX | 1 | PHASE2 | ARGX-121 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-097 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |
JADE101 is an investigational small molecule drug being developed by Jade Biosciences, Inc. for the treatment of IgA Nephropathy, a kidney disease. It is currently in Phase 2 clinical development and is designed to target APRIL, a cytokine. JADE101 has not been approved by the FDA and remains under clinical study.
JADE101 is being studied for the treatment of IgA Nephropathy, a kidney condition. It is an investigational therapy in Phase 2 development and has not been approved for any indication. Its clinical program is focused on evaluating its use in adults with this disease.
JADE101 targets APRIL, a cytokine. APRIL belongs to the tumor necrosis factor ligand family and is involved in immune signaling. By targeting this cytokine, JADE101 is being developed as a small molecule therapeutic for IgA Nephropathy, a kidney disease driven in part by immune system activity.
JADE101 is being developed by Jade Biosciences, Inc., which trades under the ticker JBIO. The company is advancing the drug as a small molecule therapy for IgA Nephropathy. Jade Biosciences is the sponsor of the ongoing clinical program for JADE101.
JADE101 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 2 program is currently recruiting participants and is focused on evaluating JADE101 in adults with IgA Nephropathy.
JADE101 is being studied in one active clinical trial, NCT07541287, titled A Study of JADE101 in Participants With Immunoglobulin A Nephropathy. The trial is a Phase 2 study that is currently recruiting approximately 30 participants across the United States, Australia, New Zealand, South Korea, and Taiwan.